JAMA recently published a series of very exciting papers from high-quality studies on the clinical benefits and risks of laparoscopic obesity surgery. Here, we present the highlights and key findings from the Diabetes Surgery Study 5-year results by Sayeed Ikramuddin and colleagues 1 and a large retrospective cohort study by Orna Reges and colleagues 2 . The Diabetes Surgery Study 1 is one of the 11 published randomized controlled trials (RCTs) comparing metabolic surgery with best medical treatments (lifestyle combined with pharmacotherapy) for patients with obesity and type 2 diabetes mellitus (T2DM). What differentiates this trial from most of the others is that the investigators did not just compare Roux-en-Y gastric bypass (RYGB) surgery with a lifestyle intervention, but a lifestyle intervention with and without RYGB. While this might sound like a nuance it could represent a paradigm shift. The effects of surgery on glycaemia and weight are so impressive that until recently many clinicians reduced or even stopped effective pharmaco therapy for glycaemia, blood pressure and dyslipidaemia, as well as lifestyle interventions soon after these procedures. The realization that even the effects of 'almighty' surgery diminish over time has shifted the paradigm in clinical care; thus, in this trial RYGB was used as yet another tool against T2DM that was added to a lifestyle intervention and existing pharmacotherapy, At 5 years, 23% of patients in the RYGB group versus 4% in the non-RYGB group achieved the primary outcome compared with 50% and 16%, respectively, at 1 year after intervention. The investigators are probably being too modest by calling the RYGB effects 'modest' . Based on their baseline severity and duration of hyperglycaemia, the participants were a group of patients with difficult-to-control T2DM. We would argue that the combined effects of lifestyle intervention plus pharmacotherapy plus RYGB remain impressive even at 5 years after intervention. Indeed, the medium to long-term maintenance of 6% weight loss in the non-RYGB group is to be applauded. In fact, we argue that if the number of cardiometabolic medications used in the RYGB group were not decreased over time, even more patients would have achieved the primary end point. One of our few criticisms of the study is that they might have diminished their own potential to achieve better HbA 1c , LDL cholesterol and blood pressure outcomes by decreasing the number of drugs over time. Downwards dose titration would have been sufficient to prevent theoretical adverse effects while still maintaining the benefits of aggressive risk factor reduction. The crossover of only 15% of patients from the non-RYGB group is very encouraging for future trials as it confirms that long-term RCTs in this field are feasible.
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As expected there were more adverse effects in the RYGB group, but in absolute terms these are still very low and confirm that with appropriate multidisciplinary team care, including aggressive micronutrient supplementation, adverse effects can either be prevented or their clinical impact minimized. The catastrophic stroke in one of the patients in the RYGB group and the pancreatic cancer in one of the patients in the non-RYGB group should not dissuade clinicians from being pro-active with their treatments for this high-risk patient group 1 . For many of our patients, the option of doing nothing can be more dangerous than doing something.
Complementing the RCT, the retrospective study performed by Reges and colleagues focused on obesity and the association between obesity surgery with reductions in all-cause mortality 2 . The investigators obtained their data from a predominantly public health-care system that covers half the in the same way that a glucagon-like peptide 1 (GLP1) receptor agonist could be added to metformin and a sodium-glucose cotransporter 2 (SGLT2) inhibitor if a patient's glycaemic control was suboptimal. Being a progressive disease, no clinician expects that a GLP1 receptor agonist will control glycaemia forever, and the same thinking should now apply to metabolic surgery. This Diabetes Surgery Study (DSS) trial was performed across four centres, two in the USA and two in Taiwan, thus increasing the generalizability of the results. The investigators randomized 120 participants to truly intensive lifestyle intervention for 2 years with or without RYGB. The intervention was based on what is considered to be the gold-standard Look AHEAD and Diabetes Prevention Program lifestyle modification and included ~30 lifestyle 'modules' and 325 minutes of prescribed physical activity per week. After the 2 years of intensive intervention, participants returned to usual care with their primary care physician, that is, to a real-life setting. The primary end point was the simultaneous achievement of the 2008 American Diabetes Association composite triple end point of HbA 1c <7%, LDL cholesterol <100 mg/dl and systolic blood pressure <130/80 mmHg, thus shifting the focus away from both the glucocentricity of previous trials and the nebulous concept of diabetes remission.
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Israeli population. They identified ~8,000 patients who underwent obesity surgery and matched them with 25,000 patients who underwent usual care for their obesity, in terms of BMI, age, sex, socioeconomic status, T2DM, hypertension, hyperlipidaemia, cardio vascular disease and smoking. The strengths of this study are the large size of the cohorts, the 4 year median duration of followup, the impressive 92% rate of complete follow-up and the inclusion of the three most commonly performed procedures around the world -RYGB, vertical sleeve gastrectomy and adjustable gastric banding.
The investigators found that patients who underwent obesity surgery were roughly half as likely to die from any cause compared with patients who did not have surgery (1.3% rate of all-cause mortality in the surgical group versus 2.3% in the non-surgical group). In addition, patients who underwent surgery benefited from higher rates of T2DM remission and lower rates of incident T2DM and hypertension. Surprisingly, there were no significant differences between the groups in terms of incident major cardiovascular events (P >0.05) in contrast to what was observed previously in the Swedish Obese Subject study (P = 0.01) 3 . In addition, no significant differences were observed when comparing the three surgical procedures in terms of all-cause mortality (P = 0.52). While the real-life nature of this study is a strength, the lack of information as to what the usual care for obesity included and the lower socio economic status of the non-surgical group at baseline are weaknesses. Despite this, patients in the usual care group managed to lose around one BMI point, which is clinically important.
In summary, these studies add to our current knowledge on the safety and effectiveness of laparoscopic obesity surgery on not only weight or glucose levels but also clinically relevant and hard outcomes in the medium to long term. Despite initial enthusiasm, it is very unlikely that metabolic surgery alone, or any non-surgical intervention such as severe long-term caloric restriction followed by food reintroduction 4 with or without medication, will deliver the long-term effects on health and mortality that we need. Metabolic surgery is effective, but if we can embrace the
